21 results
8-K
IMGN
Immunogen, Inc.
8 Feb 24
Other Events
7:08am
Antitrust Improvements Act of 1976, as amended (the “HSR Act”). ImmunoGen and AbbVie each filed a Notification and Report Form pursuant to the HSR Act
8-K
IMGN
Immunogen, Inc.
31 Jan 24
Submission of Matters to a Vote of Security Holders
4:12pm
closing conditions, including the expiration or termination of any applicable waiting period (or extension thereof) under the Hart-Scott-Rodino Antitrust
DEFA14A
IMGN
Immunogen, Inc.
29 Jan 24
Additional proxy soliciting materials
5:01pm
-Rodino Antitrust Improvements Act of 1976, as amended, and the approval of the Merger Agreement by the holders of at least two-thirds of the outstanding
8-K
IMGN
Immunogen, Inc.
29 Jan 24
Other Events
5:00pm
period (or extension thereof) under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the approval of the Merger Agreement
DEFA14A
IMGN
Immunogen, Inc.
8 Jan 24
Additional proxy soliciting materials
4:12pm
filing of a Notification and Report Form pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”). ImmunoGen
8-K
8l1eo2y
8 Jan 24
Other Events
4:11pm
DEFM14A
29hrjumq5im4
2 Jan 24
Proxy related to merger
4:26pm
PREM14A
9w7ly216dsx2 ckax
21 Dec 23
Preliminary proxy related to merger
4:52pm
DEFA14A
l0lgr2vixu8v q4l
30 Nov 23
Additional proxy soliciting materials
4:07pm
DEFA14A
EX-2.1
4zko5bvm
30 Nov 23
Additional proxy soliciting materials
4:07pm
8-K
9wtigg iez4j
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm
8-K
EX-2.1
at7u73p sc4yv1d
30 Nov 23
AbbVie to Acquire ImmunoGen, including its Flagship Cancer Therapy ELAHERE® (mirvetuximab soravtansine-gynx), Expanding Solid Tumor Portfolio
4:05pm